Close Menu

NEW YORK – With its first US Food and Drug Administration clearance of an instrument and assay, Akonni Biosystems now plans to build up a menu of diagnostic panels for complex diseases that require detection of tens to hundreds of biomarkers. 

The Frederick, Maryland-based firm intends to capitalize on the low cost of its technology, higher multiplexing capabilities compared to most competitors, and the potential to test for nucleic acids, proteins, or perform enzymatic reactions using its proprietary array-based technology.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.